Home › Funds › Kooman & Associates › GSK

Kooman & Associates position in GSK

GSK PLC · Health Care

Kooman & Associates reported holding 5,741 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$277K, representing 0.07% of its reported portfolio and ranking #49 among its reported holdings. Kooman & Associates has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.74K sh
Reported value held$276.54K
Portfolio Weight0.07%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Kooman & Associates's GSK position evolved

Kooman & Associates first disclosed a stake in GSK in Q3 2023 at 6,229 shares (US$226K). The position peaked in Q4 2025 at 7,254 shares, worth US$356K. Across 12 filings, Kooman & Associates increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 5,741 shares valued at US$277K — an increase of 49 shares quarter over quarter.. Notable position changes include a 38% increase in Q2 2025 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.23K $225.80K New
Q4 2023 6.27K $232.33K Add
Q1 2024 6.23K $267.04K Reduce
Q2 2024 6.23K $239.82K Hold
Q3 2024 6.23K $254.64K Hold
Q1 2025 5.69K $220.51K New
Q2 2025 7.83K $300.83K Add
Q3 2025 7.82K $337.30K Hold
Q4 2025 7.25K $355.74K Reduce
Q1 2026 5.69K $314.14K Reduce
Q2 2026 5.69K $298.38K Hold
Q3 2026 5.74K $276.54K Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 20 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has Kooman & Associates held GSK?

Kooman & Associates has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is Kooman & Associates's current position in GSK?

As of Q3 2026, Kooman & Associates holds 5.74K shares of GSK (GSK PLC), valued at $276.54K, representing 0.07% of its reported portfolio and ranking #49.

Has Kooman & Associates been buying or selling GSK?

In the latest 13F filing (Q3 2026), Kooman & Associates increased its position in GSK. The position peaked in Q4 2025 at 7.25K shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.